Serina's Slow-Release Apomorphine Patch Clears Safety Review in Parkinson's Trial

Parkinson's disease is one of aging's most visible assaults on functional independence. 'OFF' episodes — sudden, unpredictable lapses in motor control that occur when standard dopamine medications wear off between doses — can happen multiple times a day and rapidly erode the quality of life that healthspan is meant to protect. A drug capable of smoothing these fluctuations wouldn't just treat a disease; it would preserve the physical autonomy that makes extra years worth living.

Serina Therapeutics is pursuing that goal with SER-252, a long-acting, subcutaneous formulation of apomorphine built on the company's proprietary POZ Platform drug-optimization technology. On September 9, 2026, the company reported that an independent Safety Monitoring Committee had reviewed data from Cohort 1 of its Phase 1b trial and cleared the study to advance to a higher dose cohort.

Cohort 1 enrolled eight patients randomized three-to-one between SER-252 and placebo under double-blind, placebo-controlled conditions. Participants were temporarily withdrawn from their standard Parkinson's medications to allow a clean assessment of SER-252 alone. At the lowest dose tested, the drug produced a pharmacokinetic profile consistent with sustained, long-lasting apomorphine exposure, alongside exploratory signals of improved motor function in individual patients.

These are early, blinded, small-sample observations — not proof of efficacy. The company is careful to frame them as preliminary. The full SER-252-1b trial plans five single-dose cohorts (40 patients) followed by up to three multiple-dose cohorts (48 additional patients) across sites in the US, Australia, South Korea, and Taiwan. Topline data from the single-dose phase is expected in the first half of 2027.

For longevity-focused readers, the implications are straightforward: continuous dopaminergic stimulation delivered transdermally could reduce the motor unpredictability that forces older adults with Parkinson's into dependency far earlier than the disease's endpoint. That is a direct healthspan intervention — protecting functional years, not merely extending biological ones.